Initially understood to be a key regulator of IFNγ producing helper T-cells, our knowledge of T-bet's functional roles has expanded considerably to encompass a growing range of cellular lineages. In addition to regulating other IFN producing adaptive immune cells, it is now apparent that T-bet plays a fundamental role in the regulation of innate immune responses across mucosal surfaces. This homeostatic role is highlighted by the spontaneous colitis that occurs when T-bet is deleted from innate immune cells in RAG -/mice. Using this model as a focal point, we review our understanding of T-bet's regulation of adaptive and innate immune systems, focussing particularly on mucosal populations including innate lymphoid cells, dendritic cells, and intraepithelial lymphocytes. With the increasingly diverse effects of T-bet on different lineages, the classical binding-centric paradigm of T-bet's molecular functionality has increasingly struggled to account for the versatility of T-bet's biological effects. Recent recognition of the synergistic interactions between T-bet and other canonical transcription factors has led to a co-operative paradigm that has provided greater explanatory power. Synthesising insights from ChIP-seq studies and evolutionary biology, we expand the co-operative paradigm further and suggest a network approach as a powerful way to understand and model T-bet's diverse functionality.
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Introduction
The T-box family of proteins are an ancient, evolutionary conserved, family of transcription factors with key roles in development mediated through highly specific patterns of expression that are tightly regulated through both time and space (1, 2) . T-BOX21 (TBX21), or T-box factor expressed in T-cells (T-bet), was first cloned, in 2000, as a transcription factor specific to interferon-gamma (IFNγ) producing helper T-cells that could account for the subtype specific production of this cytokine (3) . Since this original description, an exponential growth in T-bet related research has solidified our understanding of T-bet as a key regulator of adaptive immunity.
In recent years, however, it is increasingly clear that T-bet has wide ranging functions outside of helper T-cell biology (4) . In particular, in the setting of the mucosal surfaces, T-bet has been found to regulate the developmental pathways of a wide variety of both innate and adaptive immune cells, including innate lymphoid cells (ILC) and
intraepithelial lymphocytes (IEL). Alongside this emerging role in the ontogeny of several cellular lineages, T-bet has also been found to actively regulate innate mucosal immune responses as demonstrated by the spontaneous communicable ulcerative colitis which develops in the setting of T-bet deficiency, in mice lacking adaptive immune cells (5) .
As our knowledge of T-bet's diverse cell-specific functions has grown, and with the discovery of innate lymphoid cells, a paradigm has emerged where T-bet is now conceptualised not only as a 'master regulator' of T helper 1 (Th1) cells but as a broad, conserved regulator, of type 1 immune responses (4) . A picture that is supported by the general conservation of type 2 and type 3 responses, and their respective transcription factors, GATA-binding protein 3 (GATA-3) and retinoic acid-related orphan receptor gamma (RORγt), across mammalian evolution (4) . Notwithstanding this shift in conceptualisation, our classical understanding of T-bet's molecular functionality, which we refer to as a binding-centric paradigm, has increasingly struggled to account for the increasingly divergent effects of T-bet in a growing number of immune cells. If T-bet's binding to select gene promoters and enhancers containing its T-box recognition motif, as classically understand, is ipso facto sufficient to drive specific patterns of gene expression, how is it that T-bet binding can have such contrasting effects in different cellular lineages? To explain this paradox, we synthesise emerging empirical evidence into a network theory of T-bet functional effects, where it is argued that the functionality of this transcription factor is dependent on the network of transcription factors already present within a cell thus explaining how T-bet's expression can regulate diverse, even opposing, functional programs in different cellular milieus.
There have been many excellent reviews of the role of T-bet in adaptive immune cells (6, 7) . This review focuses on T-bet's role in governing mucosal immune responses given the increasing realisation of the unique properties of mucosal immune responses and their relevance to human health. A key focus of the review is on the molecular functions of T-bet that are able to account for the variety of its functional effects within different settings. As most of our understanding of the molecular functionality of T-bet has arisen from studies in helper T-cells, we begin by reviewing what has been learnt from T-bet's role in helper lymphocytes. Subsequently, we present the T-bet deficient model of colitis in recombination activating gene (RAG) knock-out mice as a powerful model for capturing the interconnected functions of T-bet on the innate immune landscape of the intestinal mucosa. We explore the role of T-bet in key mucosal populations such as innate lymphoid cells, intraepithelial lymphocytes and dendritic cells. These cellular lineages are highlighted, in particular, as they showcase the contrasting ways in which Tbet can regulate diverse cell fates. These contrasting roles are used as a background to introduce the network theory as an adaptation of the co-operative paradigm increasingly popular in molecular immunology. We discuss the therapeutic potential of targeting Tbet, and finally summarise key outstanding questions in the molecular biology of T-bet.
T-bet as a 'master-regulator' of helper T-cells and the emergence of the classical paradigm of immune transcriptional regulation.
The discovery by Mossman and Coffman of distinct types of helper T-cells, established one of the central paradigms of immunology: that adaptive immune responses in addition to being quantitatively tuned to antigen, through clonal selection, are also qualitatively tuned through the selection of unique effector programs (8) . Despite the accumulation of substantial in vivo evidence supportive of this paradigm, it would take 10 years before a molecular explanation could be provided to account for the unique effector programs of helper T-cells. The identification of GATA-3, in 1997, followed by T-bet, three years later, as subtype specific transcription factors established a paradigm of 'master-regulators' controlling specialised cell fates (3, 9) . This mode of thinking has deeply influenced immunologists, as illustrated by the reluctance to fully accept newly proposed lineages such as the T helper 22 (Th22) or T helper 9 (Th9) lineages, which lacking a unique transcription factor fail to dovetail smoothly into this paradigm.
Early hypothesis-driven studies into the molecular effects of T-bet focused on key functional loci known to be differentially expressed between helper T-cell subsets, such as IFNγ and interleukins 4 (IL-4) and 5 (IL-5) (10). These early studies, using genereporter assays, identified the specific in-cis up-regulation of T helper 1 (Th1) specific cytokines through T-bet binding and the reciprocal inhibition of competing cytokines. A crucial insight, made early in the analysis of T-bet, is that while positive gene regulation arises from T-bet's interaction with DNA, negative regulation, in many instances, occurs through protein-protein interactions with other canonical immune regulators (11) . This negative regulation is illustrated by phosphorylation of GATA-3 by T-bet which functions to repress the GATA-3 program in Th1 cells partly through the re-direction of GATA-3 from its default binding sites (11).
Thus a model arose whereby the specific binding of T-bet to core promoters was understood to cause up-regulation of a lineage-specific transcriptional program while inhibiting opposing cellular programs, in-part, through protein interactions. So well did the available empirical data fit this model, that it has led historically to a heavily determined view of T-bet, whereby this transcription factor alone was believed to be 'necessary and sufficient' for the differentiation of Th1 cells. Central to this paradigm was the view that specific binding patterns of T-bet, as informed by hypothesis driven gene reporter assays, were ipso facto sufficient to account for the transcription factor's positive genomic effects (6) . 
Wider roles for T-bet in adaptive immune response and the emergence of Tbet as central regulator of mucosal homeostasis.
With the emergence of the influential Th1/Th2 dichotomy, a paradigm emerged A significant development in T-bet biology, was the discovery that T-bet could regulate mucosal homeostasis and the homeostatic response to intestinal microbiota (5, 18) . This, in addition to being a further quantitative expansion, was also a qualitative expansion as T-bet plays a very different role in these cells compared to other adaptive immune cells. The mucosal surfaces of the human body, including those of the respiratory and the digestive tract account for a combined surface area of 300m 2 , and are host to a significant microbial load with over 10 12 bacteria/cm 3 in the colon alone (19) .
The mucosa, therefore, represents the primary site of exposure to non-self, and has a unique immune architecture, or MALT (mucosa associated lymphoid tissue) that facilitates this homeostatic role.
Amongst the earliest evidence for a T-bet specific role in mucosal immune responses is the unexpected development of spontaneous colitis in mice who lack T-bet in the innate immune compartment (20) .
is characterised by inflammation limited to the colon that histologically mimics human ulcerative colitis. Pathology in TRUC arises through a series of well characterised events, summarised in Figure 
T-bet's role in the development and regulation of mucosal immune cells.
A key event in the development of TRUC, is the outgrowth of gram-negative bacteria in the colon. At the time of the original description of TRUC, it was not recognised that T-bet regulates the development of ILC1s and NKp46+ ILC3 populations (24) (25) (26) . It is thus likely that the selective outgrowth of gram negative bacteria observed in TRUC is a direct consequence of the absence of these T-bet expressing innate populations (20) . Recently, it has been observed that T-bet dependent ILC1s, and to a lesser extent NKp46+ ILC3s, play an obligate role in the immunity of RAG-/-mice to Clostridium difficile, thus providing supportive evidence in-favour of a cell intrinsic mechanism leading to dysbiosis in TRUC (27) . Given the central role of TRUC, in enhancing our understanding of T-bet biology, we briefly review the role of T-bet in the development and function of innate lymphoid cells (ILCs), dendritic cells and intraepithelial cells.
Innate Lymphoid Cells
Innate lymphoid cells (ILCs) are CD45+, lineage negative (Lin-) cells that arise from a common lymphoid precursor in the bone marrow (28) . Though rare in blood and secondary lymph organs, they are enriched in the mucosal regions of the body including the lungs and intestine and have been found to have important roles in mucosal defence against pathogenic bacteria. ILCs lack antigen-specific receptors, yet share many parallels with helper T-cells (29) . The most marked parallel is their subdivision into three groups on the basis of their ability to produce type 1 (IFNγ), type 2 (IL-4, IL-13) and type 3 (IL-17, IL-22) cytokines. In parallel, with helper T-cells: these three groups share a typespecific transcription factor (29) . ILCs are of particular excitement, because the production of specialised cytokines was previously believed to be a unique feature of helper T-cells. ILCs, however, reveal that there is an innate source of these cytokines, which shares conserved mechanisms of transcriptional control -thus leading to a revaluation of some fundamental immunological principles. T-bet, in addition to defining type 1 ILCs, is also expressed in a subset of type 3 innate lymphoid cells (30) . this has been particularly true for a TRAIL+ population of liver NK cells (33) . This liverspecific population, in contrast to TRAIL -DX5 + conventional splenic NK cells (cNK) has a CD49a+ DX5-phenotype, and thus was originally classified as a liver-resident immature NK cell population (34) . Careful fate-mapping experiments, however, have shown that like ILC1s, liver-resident NK cells are abrogated with T-bet deletion, and develop independently of EOMES (34, 35) . Phenotypically, liver-resident NK cells more closely match ILC1s expressing, for example, CXCR6, which is not expressed in cNKs (35) . Functionally, liver-resident NK, like ILC1, show less cytotoxic activity in tumour lysis assays in comparison to cNKs (36) . Thus, despite heterogenic expression of CD127 and CD27, the preponderance of evidence supports the notion that liver-resident NK cells are best conceptualised as a subset of T-bet dependent ILC1s, distinct from cNKs. ChIP-seq data, in addition, also militates against the binding centric view. While this data has been interpreted to support a binding-centric paradigm, it also allows for a different interpretation. Studies of genomic T-bet binding have consistently shown, that regulated loci account for a small proportion of discernible binding events across a genome. For example, transcriptional profiling availing T-bet -/mice, has placed the number of genes positively regulated by T-bet at approximately 2 x 10 2 (48) .
Interestingly, when ChIP-seq is used to analyse T-bet binding sites, the number of T-bet binding sites is over fifty-fold higher, in the region of 1 x 10 4 (10) That is, the vast majority of genomic T-bet binding does not result in transcriptional events. Therefore, as most genomic binding is not accompanied by transcriptional regulation: it is either the character of the promotor, or some other factors present that must determine why some loci are functionally regulated by T-bet while the majority are not effected by T-bet's presence. Indeed, there is a precedence for such a model in the regulation of T-cell differentiation, where disinhibition of Inhibitor of DNA-binding protein 1 (ID1) is required for GATA-3 mediated gene expression, despite sufficient binding of GATA-3 to genomic locias it is the presence of E-proteins, liberated from sequestration by ID1, at these loci that induces transcription where GATA-3 is present (49) .
There has been substantial recognition of the role played by protein-protein interactions between immune lineage determining transcription factors in negative gene regulation. With the expansion of the Th1/Th2 paradigm to encompass Th17 cells, this view has remained robust with T-bet known to negatively regulate Th17 gene expression through interactions with RUNX-1. The increasing recognition of immune plasticity and cells that express multiple lineage transcription factors has given rise to the co-operative paradigm, whereby positive gene regulation is understood to arise from the interaction or co-operation of multiple canonical transcription factors (7) . This is powerfully demonstrated in regulatory T-cell (T-reg) biology where the co-expression of T-bet and both GATA-3 alongside FOXP3 has been shown to be essential for optimal suppressive activity in vivowith T-regs void of these two factors deficient in function (50) .
In postulating a network theory we take the co-operative model a step further. We postulate that even in cells expressing a single canonical immune regulator such as Thelper 1 cells or ILC1s, that transcriptional control can best be understood as the output of a network of co-interacting transcription factors, rather than as output of single or small collection of canonical regulators. The attraction of such a theory is that it provides a way to understand how the varied roles of T-bet in-vivo can arise. For example, in dendritic cells, the basal transcription factors within the cell that are distinct from those in helper T-cells are thus likely to explain why in this setting T-bet has unique roles in TLR signalling and why TNF is uniquely repressed in contrast to other cells where T-bet transactivates this gene.
While it may be tempting to explain away the contradictory roles of T-bet in some cells as the function of hitherto undiscovered protein interactions that are specific to each background lineage, the network theory provides a more systematic and biologically intuitive model that ties together observations from comparative proteomics and ChIPseq. The strongest evidence for a network theory comes from the most exhaustive study of a canonical immune transcription factor undertaken to-date (51). Wei and colleagues, using ChIP-seq, assayed genome-wide binding of GATA-3 in nine different immune population including the main helper T-cell lineages (Th1, Th2, Th17, natural Treg) and the main thymic T-cell precursors. In line with the T-bet ChIP-seq data presented above, they found that GATA-3 binding induced detectable effects on gene expression on a minute proportion of the total loci bound. Furthermore, as described with T-bet in DCs and IELs, they found that GATA-3 binding at a specific locus could induce either gene activation or repression depending on the cellular context. Additionally they identified a large number of cell specific GATA-3 binding sites, despite conservation of the GATA-3 motif as derived empirically from their data. This substantial cell specificity identified, in even closely related cells, supports our contention that it is the network of factors present with the cells, and not the physical characteristics of the transcription factor, that determines biological outputs.
The network theory is thus a falsifiable model of transcriptional interaction at the far end of a continuum that has evolved from single driver reductionism (master regulator) to one of nuanced nodal interactions (co-operative) to one of sophisticated biological complexity.
Therapeutic targeting of T-bet.
T-bet has been implicated in a large number of inflammatory diseases (52) . In the context of IBD, T-bet has been found to be up-regulated in mucosal biopsies of patient's with Crohn's disease (53) . Given the central role of T-bet in maintaining immune homeostasis, even the attenuation of T-bet activity can lead to disease as emphasised in the TRUC pre-clinical model where the absence of T-bet triggers microbial dysbiosis.
Significantly in Asthma, despite no signals from large Genome Wide Association Studies (GWAS) studies, T-bet polymorphisms have been linked repeatedly, through candidategene studies, to increased disease severity mediated through an increased disposition to Th2 differentiation (54) (55) (56) . As such, modulation of T-bet biologically has long been considered an attractive therapeutic targetwith both upwards and downwards modulation of T-bet desirable across a range of diseases.
Despite this theoretical attractiveness, transcription factors are inherently difficult to pharmacologically target due both to their intra-nuclear location, which precludes antibody based approaches, and also the inherent difficulty of targeting protein-DNA interactions given their large interaction domain. As such, transcription factors have been traditionally regarded as un-drugable (57) . Given the difficulties of a small molecule approach, it is perhaps not surprising that most attempts at targeting T-bet therapeutically have centred on gene silencing approaches. By relying on the principle of base-pair complementarity and siRNA, such approaches bypass the need for complex protein or small-molecule engineering. In vivo, this approach has been used successfully in a range of pre-clinical models including in Experimental Allergic Encephalitis (EAE) (58) . The
Achilles heel of such genetic approaches is the difficulty of specifically targeting fragile oligonucleotides in vivo. This obstacle is mitigated by topical delivery around which most translational efforts have focused. Recently, a land-mark Phase II study of inhaler delivered oligonucleotides targeting GATA-3 achieved primary end points, highlighting the potential of this approach (55) . This was a significant breakthrough as a succession of monoclonal antibodies targeting numerous promising cytokines in asthma have all failed at the randomised control trial (RCT) stage, and thus this success underscores the therapeutic potential of targeting transcription factors directly. Following this early success, this approach targeting GATA-3 is currently being applied to Ulcerative Colitis in Phase II trials (ClinicalTrials.gov: NCT02129439). Separately, a T-bet inhibitor, based on the same gene silencing approach, is currently in pre-clinical development (59) .
Alongside the development of gene silencing approaches to target transcriptionfactors, the notion that transcription factors are un-drugable has been recently challenged by the development of small molecule inhibitors for the immune regulator, RORγT (60) .
This development, the result of high-throughput library screening followed by targeted chemical optimisation, has resulted in a number of compounds that inhibit RORγT activity both in vitro and in vivo, including an oral inhibitor. The lessons learnt from this approach have huge implications for therapeutics and basic transcription factor biology.
In a study by Xiao et al, of three RORγT inhibitors developed, the most therapeutically effective, TMP778, moderately inhibited DNA-binding (61) . In contrast, the most effective DNA-binding inhibitor in this study, TMP920, as determined empirically by ChIP-seq, was the least effective in the preclinical EAE autoimmune disease model -thus this data would seem to support the idea postulated by the network theory that it is proteinprotein interactions that underscore transcription factor function. The rationale and catalyst, for the development of such inhibitors for RORγt was the view that Th17 cells are the most dominant cell in autoimmunity and thus the potentially large market for such a therapy. The recent widespread consensus that pathogenic Th17 cells actually coexpress and require T-bet for pathogenicity, further underscores the therapeutic potential of targeting T-bet in this manner (31, 62, 63) .
Conclusion and unanswered questions in T-bet biology.
In summary, we have focused on the emerging role of T-bet in the mucosa and in particular used the highly idiosyncratic effects of T-bet on DCs and IELs, that are mirror opposites of T-bet's standard effects on helper T-cells, to argue that structural determination of T-bet genomic binding through a conserved T-box recognition motif is insufficient to account for its increasingly diverse molecular effects. We have used to much rarer populations including innate immune cells and DCs that have not been amenable to traditional ChIP-seq assays (64) . Furthermore, despite the existence of several transcriptional data-set from various T-bet deficient cells, there has been no attempt to integrate these systematically to analyse which T-bet targets are specific or unique to any of the lineages regulated by T-bet.
The empirical data suggests, and indeed as our network theory argues, that there are large numbers of T-bet protein interactions that are yet to be determined. While we currently know of over a dozen direct protein interaction between T-bet and other factors as illustrated in Figure II , these have largely been determined on a single molecule hypothesis driven basis. Robust determination requires system wide proteomics to detect such interactions in a systematic un-biased manner, as it is likely that these underlie cellspecific transcriptional effects. Determination of these effects is also likely to have implications for therapeutics as the experience with small molecular targeting of RORγt suggests that these protein-protein interactions are the key desirable target. Further elucidation of these networks may provide a manner to specifically target T-bet in distinct lineages, through targeting of T-bet's interactions with cell-specific interaction partners.
Remarkably despite the huge potential of evolutionary approaches to deduce regulatory networks through conservation, this approach has remained largely untapped in immunology. Such approaches with other tissue specific transcription factors have yielded huge insights and are likely to do the same in immunology. As such, our broadened understanding of T-bet's functional roles is likely to expand from the classical reductionist paradigm into the era of systems biology. This increased understanding, coupled with success at translating this into effective therapeutics may eventually herald the long-awaited translation of our knowledge of the canonical role of T-bet on immune responses into concrete therapeutics. Contributing to pathology is the selective outgrowth of gram negative pathogenic microbiota induced by an undefined deficiency in the innate immune system (A. and B).
This outgrowth of pathogenic microbial species is detected by mucosal DCs, which produce IL-23 and increased levels of TNF in the absence of T-bet (C.), leading to epithelial cell apoptosis and increased ILC3 activation (D). Activated ILC3s produce IL-17 and IL-22 leading to further mucosal pathology from neutrophil recruitment and activation.
Figure II: T-bet (TBX21) interaction partners.
STRING interaction graph showing T-bet's (TBX21) known experimentally determined
protein -protein interaction partners in Mus Musculus (65) 
